Description
TRV-120027, also known as TRV027 TFA, is a novel peptide-based analog of angiotensin II that uniquely biases signaling toward ?-arrestin pathways at the angiotensin II type 1 receptor (AT1R), while inhibiting traditional G-protein–mediated vasoconstriction. This pharmacological profile enables simultaneous promotion of vasodilation, enhancement of cardiomyocyte contractility, and anti-apoptotic actions. These effects combine to provide potent cardioprotection, particularly relevant in acute heart failure settings. Developed under GMP conditions with high pharmacological grade purity (?98%), TRV-120027 is an advanced research tool for cardiovascular, renal, and pharmacodynamic investigation.
Product Category
Cardioprotective Biased Ligand Peptides — synthetic peptides that selectively activate signaling bias, used in heart failure, cardiovascular modeling, and receptor-signaling research.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | TRV-120027 TFA |
| Synonyms | TRV027, TRV 120027 |
| CAS Number | 1234510-46-3 |
| Purity | ?98.0% |
| Classification | ?-arrestin-biased AT1R agonist peptide |
| Molecular Formula | C??H??N??O?? |
| Molecular Weight | ?926 Da |
| Mode of Action | AT1R signaling via ?-arrestin, G-protein pathway blocked |
| Appearance | White to off-white powder |
| Solubility | Soluble in DMSO and aqueous media |
| Storage | –20 °C; store dry and protected from light |
| GMP Compliance | Yes — produced in GMP-certified facility |
Mechanism of Action & Research Applications
TRV-120027 binds AT1R and shifts its signaling from G-protein–mediated vasoconstriction to ?-arrestin–mediated cardioprotective responses. Key actions include:
Vasodilation by antagonizing G-protein pathways
Enhanced cardiomyocyte contractility via ?-arrestin engagement
Anti-apoptotic effects, aiding cell survival in cardiac stress
In heart failure models, especially when combined with diuretics like furosemide, TRV-120027 reduces cardiac preload and afterload, maintains renal performance, and enhances cardiac output—making it highly relevant for studies on acute heart failure, renal function, and biased agonist pharmacotherapeutics.
Side Effects (For Research Context Only)
Experimental studies show effective hemodynamic targeting at controlled doses. Researchers should monitor cardiovascular markers to avoid hypotension. The ?-arrestin bias limits typical angiotensin II–mediated side effects, but safety monitoring remains essential.
Logistics Transportation
All shipments are insurance-covered to guarantee safe and prompt delivery. We offer 100% compensation for any lost, detained, or damaged items.
Disclaimer
This product is strictly intended for laboratory research use only. It is not approved for therapeutic, clinical, or veterinary purposes.


Reviews
There are no reviews yet.